Bulletin of Experimental Treatments for AIDS, No. 3, June 1989
AZT for asymptomatic HIV positive individuals (019).
Bactrim and aerosolized pentamidine for prophylaxis of PCP for PWA taking AZT (021).
Phase I trial of AZT and IL 2 for people with persistent general- ized lymphadenopathy (024).
AZT for asymptomatic, HIV positive hemophiliacs (036).
Phase I/II trial of alternating and intermittent regimens of AZT and ddC for PWA and PWARC (047).
Phase I/II trial of alternating and intermittent regimens of AZT and ddC for people who have experienced hematologic toxicity from AZT (050). cell mediated cytotoxicity and lymphocyte prolifera- tion responses in asymptomatic, HIV positive individuals.
T-cell mediated cytotoxicity and lymphocyte proliferation responses in asymptomatic, HIV-positive individuals.
Phase I dose escalating trial of a new glycosylase inhibitor (SC 48334) for people with severe ARC or AIDS (100).
Randomized trial of three antipneumocystis agents plus AZT for the primary prevention of PCP (081).
890601
BETA0302
Copyright © 1989 - Bulletin of Experimental Treatments for AIDS (BETA). Reproduced with permission. BETA is published four times a year by the San Francisco AIDS Foundation. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. Call 415.487.8060; FAX: 415.487.8069. Mailing Address: P.O. Box 426182, San Francisco, CA 94142-6182. beta@sfaf.org http://www.sfaf.org/beta.html